Treatment with the STING agonist DMXAA significantly decreased expression of the tight junction proteins (TJPs) ZO-1 and occludin in human colorectal adenocarcinoma cell HT-29 and in the DSS-induced colitis mouse model when compared to DSS treatment alone (159). The gene discussed is STING1; the disease is colitis.